Does Aetna Cover Forteo?

How Aetna Classifies Forteo on Its Formulary

Aetna places Forteo on its specialty medication tier across nearly all plan types. This classification means higher cost-sharing and mandatory utilization management before the pharmacy can dispense it. On Aetna's 2025 and 2026 formulary documents, teriparatide appears under the "Specialty" or "Non-Preferred Brand" tier, depending on whether the plan is a commercial PPO, HMO, or Medicare Advantage product.

Specialty-tier placement is standard across major insurers for anabolic bone agents. The Endocrine Society's 2020 clinical practice guideline on pharmacological management of osteoporosis recommends anabolic therapy (teriparatide or abaloparatide) as first-line treatment for patients at very high fracture risk, defined as recent vertebral fracture, T-score below -3.0, or high FRAX probability [1]. Despite this recommendation, most payers including Aetna still require step therapy through a bisphosphonate first.

The practical impact: your prescriber cannot simply write a Forteo prescription and have it filled. The pharmacy will trigger an electronic prior authorization request, and your provider's office must submit clinical documentation to Aetna before dispensing begins. This process takes 3 to 14 business days in most cases.

Prior Authorization Criteria Aetna Requires

Aetna's clinical policy bulletin for teriparatide outlines specific criteria your provider must document. The requirements differ slightly between commercial plans and Medicare Advantage products, but the core criteria overlap.

For commercial plans, Aetna requires all of the following: a confirmed diagnosis of osteoporosis based on a DXA scan showing a T-score of -2.5 or lower at the spine, femoral neck, or total hip; documented trial and failure of, intolerance to, or contraindication to at least one oral bisphosphonate (alendronate, risedronate, or ibandronate); and age 18 or older. Aetna also considers approval for patients with glucocorticoid-induced osteoporosis who are taking prednisone 5 mg daily (or equivalent) for 3 months or longer and have a T-score of -1.0 or lower [2].

For Medicare Advantage members, Aetna follows CMS coverage determination criteria, which align closely with the commercial requirements but also accept a history of fragility fracture as a qualifying criterion even if the T-score is between -1.0 and -2.5 (osteopenia range with fracture).

Step therapy is the most common barrier. Your doctor must document that you tried a bisphosphonate for a clinically meaningful period (generally 12 months) or explain why bisphosphonates are contraindicated. Valid contraindications include esophageal disorders such as Barrett's esophagus or esophageal stricture, inability to remain upright for 30 minutes, hypocalcemia, or severe renal impairment with eGFR below 30 mL/min [3].

What Forteo Costs with Aetna Insurance

Out-of-pocket costs vary substantially by plan type. The differences can be measured in hundreds of dollars per month.

On a typical Aetna commercial PPO with specialty-tier coverage, members pay coinsurance of 25% to 33% after the deductible, which can translate to $800 to $1,200 per month before any copay assistance. Plans with a specialty copay cap may limit this to $150 to $500 per fill. Aetna's Open Choice PPO plans often include a $150 specialty copay maximum per 30-day supply, while Aetna Whole Health plans may have different cost-sharing structures.

For Medicare Advantage members, Forteo falls under Part D (self-administered injectable). During the initial coverage phase, expect copays of $50 to $200 per month. Once you enter the Medicare Part D coverage gap, manufacturer discounts under the Inflation Reduction Act reduce out-of-pocket spending to $0 starting in 2025 for qualifying beneficiaries, as the $2,000 annual out-of-pocket cap now applies [4].

The manufacturer (Eli Lilly) offers the Forteo Savings Card, which reduces copays to as low as $4 per month for eligible commercially insured patients. This card does not apply to Medicare, Medicaid, or other government-funded plans. Patients using the savings card saw average monthly costs of $4 to $25 based on the program's published data.

Biosimilar teriparatide offers a potential cost reduction of 15% to 30% at the wholesale level, though Aetna's formulary positioning of the biosimilar varies by plan and region [5].

The Step Therapy Process: What Happens First

Aetna's step therapy protocol reflects a cost-management approach common across commercial insurers. You start with a generic bisphosphonate. If it fails, Forteo becomes accessible.

The first step is oral bisphosphonate therapy. Generic alendronate 70 mg weekly costs $10 to $30 per month and is Aetna's preferred first-line agent. The Fracture Intervention Trial (FIT) demonstrated that alendronate reduced vertebral fracture risk by 47% (RR 0.53 to 95% CI 0.41 to 0.68) over 3 years in women with existing vertebral fractures [6]. This is why Aetna and other payers position bisphosphonates as the starting point.

If alendronate fails or causes intolerable GI side effects (occurring in roughly 20% to 30% of patients based on clinical practice data), your prescriber can request Forteo. Failure is defined as: a new fracture while on therapy, continued bone density decline (loss of 3% or more at the spine or hip on repeat DXA), or documented adverse effects requiring discontinuation.

One exception to step therapy: patients with very high fracture risk. The American Association of Clinical Endocrinology (AACE) 2020 guidelines define very high risk as a T-score of -3.0 or below, a recent (within 12 months) vertebral or hip fracture, fractures while on approved osteoporosis therapy, or a FRAX 10-year major osteoporotic fracture probability exceeding 30% [7]. If your prescriber documents very high fracture risk with supporting evidence, Aetna may approve Forteo without a prior bisphosphonate trial.

How to Appeal an Aetna Denial for Forteo

Denial rates for specialty osteoporosis medications are not trivial. Getting past an initial denial requires organized documentation and persistence.

When Aetna denies a prior authorization, they issue a letter specifying the reason. The three most common denial reasons for Forteo are: insufficient documentation of bisphosphonate failure, missing DXA scan results, and diagnosis not meeting medical necessity criteria. Each is addressable through appeal.

You have 180 days to file a standard (non-urgent) internal appeal and 72 hours for an expedited appeal when there is immediate fracture risk. Dr. Andrea Singer, Director of Bone Density at MedStar Georgetown University Hospital, has noted: "Peer-to-peer review calls between the prescribing physician and the insurance company's medical director often resolve Forteo denials within a single conversation when the clinical data is clearly presented."

For your appeal, assemble these documents: the DXA scan report with T-scores, documentation of prior bisphosphonate use (prescription records, duration, reason for discontinuation), FRAX score calculation, any imaging showing existing fractures, and a letter of medical necessity from the prescribing physician citing guideline recommendations. The AACE/ACE 2020 guideline and the Endocrine Society 2020 guideline both support anabolic-first therapy in very high-risk patients, providing strong evidence for appeal letters [1][7].

If the internal appeal fails, you may request an external review through your state's Department of Insurance. External reviews are decided by independent physicians not employed by Aetna.

How Forteo Compares to Other Covered Osteoporosis Agents

Aetna's formulary includes several osteoporosis medications at different cost-sharing tiers. Understanding where Forteo fits helps you and your prescriber select the most clinically and financially appropriate option.

Generic alendronate and risedronate sit at Tier 1 (preferred generic), costing $4 to $30 per month. Denosumab (Prolia) occupies the specialty tier alongside Forteo, with similar prior authorization requirements and copays of $50 to $400 per injection every 6 months. Abaloparatide (Tymlos), a second anabolic agent, is also specialty-tier and carries comparable costs and step therapy requirements.

Romosozumab (Evenity) presents a different coverage situation. Aetna classifies Evenity as a medical benefit (not pharmacy benefit) because it is administered in-office. Coverage falls under Part B for Medicare patients. The ARCH trial showed romosozumab reduced vertebral fracture risk by 48% compared to alendronate at 24 months (6.2% vs. 11.9%, P<0.001), but the cardiovascular safety signal limits its use in patients with recent MI or stroke [8].

In the VERO trial, teriparatide reduced new vertebral fractures by 56% compared to risedronate (5.4% vs. 12.0%, P<0.0001) over 24 months in postmenopausal women with severe osteoporosis [9]. This head-to-head data supports Forteo's superiority over bisphosphonates in high-risk patients, which is the clinical population most likely to receive Aetna approval.

Duration Limits and What Happens After 24 Months

Aetna authorizes Forteo for a maximum of 24 months. This aligns with the FDA-approved treatment duration based on the original registration studies and the theoretical risk of osteosarcoma observed in rat models at supratherapeutic doses.

The 24-month clock starts at first fill. Aetna will not reauthorize a second course of Forteo after the initial 24 months. This is a firm policy, not a guideline. The FDA label for Forteo states that use for more than 2 years during a patient's lifetime should only occur if the patient remains at high risk for fracture [10].

What happens after Forteo stops matters enormously. Bone density gained on teriparatide declines rapidly without sequential antiresorptive therapy. The DATA extension study demonstrated that stopping teriparatide without transitioning to a bisphosphonate or denosumab resulted in loss of 50% or more of the bone density gained within 12 months [11]. Aetna covers the transition to denosumab or a bisphosphonate after Forteo completion without additional step therapy requirements, since the patient has already documented their clinical need.

Dr. Felicia Cosman, Professor of Medicine at Columbia University, has stated: "Every patient who completes teriparatide should transition directly to an antiresorptive agent. There should be no gap. The anabolic gains are not durable without consolidation therapy."

Plan your exit strategy before starting Forteo. Discuss with your prescriber whether denosumab or zoledronic acid will follow, and confirm Aetna coverage for the sequential agent at the same time you request the Forteo prior authorization.

Special Coverage Situations: Glucocorticoid-Induced and Male Osteoporosis

Aetna covers Forteo for glucocorticoid-induced osteoporosis (GIOP) and male osteoporosis, though documentation requirements differ slightly from postmenopausal coverage.

For GIOP, Aetna requires documentation that the patient is taking systemic glucocorticoids equivalent to prednisone 5 mg or more daily for at least 3 months, plus a T-score of -1.0 or lower. The threshold is lower than the -2.5 required for postmenopausal osteoporosis because glucocorticoids impair bone quality disproportionately to their effect on bone density. The 2017 American College of Rheumatology guideline conditionally recommends teriparatide over bisphosphonates for adults aged 40 and older taking glucocorticoids who are at high fracture risk, based on evidence from the teriparatide vs. alendronate GIOP trial showing 7.2% greater lumbar spine BMD gain with teriparatide at 18 months [12][13].

For male osteoporosis, Aetna applies the same T-score and step therapy requirements as for postmenopausal patients. Men with hypogonadism-related bone loss may have an easier path to approval if they can document ongoing testosterone replacement therapy that has not adequately addressed bone density decline. The Osteoporosis in Men (MrOS) study established that men with T-scores below -2.5 at the hip have fracture rates comparable to postmenopausal women, supporting equal access to anabolic therapy [14].

Using Aetna's Specialty Pharmacy for Forteo

Aetna requires Forteo to be filled through a designated specialty pharmacy in most plans. You cannot fill it at a retail pharmacy like CVS or Walgreens under standard Aetna plans (though Aetna's CVS Caremark integration means CVS Specialty is often the designated pharmacy).

The specialty pharmacy handles prior authorization coordination, ships the medication to your home with cold-chain packaging, and provides injection training resources. First shipments typically arrive within 5 to 10 business days after prior authorization approval. Refills are shipped monthly, and the pharmacy will contact you before each refill to confirm adherence and address side effects.

If you prefer a different specialty pharmacy, ask your Aetna plan whether out-of-network specialty pharmacy benefits exist. Some self-funded employer plans administered by Aetna permit broader pharmacy access. The cost difference between in-network and out-of-network specialty pharmacies can be $500 or more per fill, so confirm network status before requesting a transfer.

Forteo pens require refrigeration at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). Specialty pharmacies ship with gel packs, but inspect the package on arrival. A pen exposed to temperatures above 77 degrees Fahrenheit (25 degrees Celsius) for extended periods should not be used. Each pen contains a 28-day supply at the 20 mcg daily dose.